Exploring the Therapeutic Effect of Telitacicept on Lupus Erythematosus Complicated With Thrombocytopenia
A Randomized Controlled Trial Aimed at Exploring the Efficacy of Telitacicept in the Treatment of Systemic Lupus Erythematosus Patients With Refractory Thrombocytopenia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Gao Guanmin
- Phone Number: 13613716851
- Email: Guanmingao@zzu.edu.cn
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Meets the 2012 ACR revised standards and meets four or more diagnostic criteria for systemic lupus erythematosus;
- Refractory thrombocytopenia (defined as receiving at least one course of methylprednisolone pulse therapy or intravenous injection of high-dose immunoglobulin or high-dose glucocorticoid combined with two or more Immunosuppressive drug failed and did not respond to any single drug);
- SLEENA-SLEDAI score is greater than or equal to 8 points. If anti ds-DNA antibody is positive and/or low complement, SLEENA-SLEDAI score is greater than or equal to 6 points, or PLT count is<10 * 10 ^ 9/L or<30 * 10 ^ 9/L with bleeding tendency;
- Age greater than or equal to 18 years old and less than or equal to 65 years old;
- Have a stable SLE treatment plan, and participants should receive standard treatment for at least 30 days before randomization; 6. Positive Antinuclear antibody or anti ds DNA antibody;
7. Sign informed documents.
Exclusion criteria:
Potential subjects who meet the inclusion criteria will be excluded if they meet any of the following criteria:
- Patients who are allergic to tamoxifen;
- Patients with severe active infection, history of tuberculosis, malignant tumor, HIV, hepatitis B, hepatitis C, important organs or hematopoietic stem cells/cells/bone marrow transplantation or kidney transplantation;
- Patients with severe active central nervous system lupus and severe active lupus nephritis
- Patients with diseases of liver, kidney, heart and other important organs, blood and Endocrine system;
- Pregnant and lactating women;
- Have a pregnancy preparation plan in the past year;
- Those who have merged with other autoimmune diseases;
- Incomplete case data and missing persons.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Treatment group
conventional treatment plus Telitacicept 160 mg sc per week
|
160mg once a week for 48 weeks
Other Names:
Steroid(≤1mg/kg/d) with or without proper immunosuppressants:CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.
|
|
Placebo Comparator: Control group
Placebo plus conventional treatment
|
Steroid(≤1mg/kg/d) with or without proper immunosuppressants:CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.
Used once a week in combination with standard treatment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The remission rate of SLE response index at month 12 of treatment
Time Frame: months 12
|
Use SRI-4 to represent the response index, with a higher response rate indicating better drug efficacy
|
months 12
|
|
Improvement in platelet count
Time Frame: months 12
|
Platelet count at month of treatment,Increased platelet count indicates improvement in disease
|
months 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of patients with a decrease of ≥ 4 points in the SELENA-SLEDAI score from baseline at months 6 and 12
Time Frame: months 6 and 12
|
A decrease of ≥ 4 points from baseline in the SELENA-SLEDAI score indicates a good drug response effect
|
months 6 and 12
|
|
Hormone reduction
Time Frame: month 12
|
Changes in patient hormone dose from baseline at month 12,reduced hormone dosage indicates improvement in disease
|
month 12
|
|
B lymphocyte count
Time Frame: month 12
|
Changes in patient B lymphocyte count from baseline at month 12
|
month 12
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Gao Guanmin, The First Affiliated Hospital of Zhengzhou University
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- GGao
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.